Who are we?
Protelica is a proven pioneer in the field of high-throughput protein engineering and optimization. Building on our extensive portfolio of patented technologies, we're applying advances in evolutionary mutagenesis to develop high affinity binding proteins that address critical unmet needs in medicine, healthcare, the life sciences industry, and clean technology. Our principal focus is to develop superior, next generation protein-based therapeutics, as well as enzymes, molecular probes, and diagnostics tools. At Protelica, we employ a patented, site-directed mutagenesis technology, which enables high affinity binding proteins to be developed in a matter of weeks, saving our industry partners both time and money, in development and production costs. The Protelica technology can be applied to virtually any peptide or protein.
April 18, 2013: Protelica Launches New Website
May 1, 2013 USPTO Notice of Allowance Marks Major Achievement for Protelica's Series of VEGFR-2 Antibody Mimics, Wall Street Journal